US Tightens Controls on Potent Kratom Compound as Safety Concerns Rise
A new wave of regulatory action targets 7-hydroxymitragynine, or 7-OH, a potent opioid-like compound found in kratom. U.S. health officials are moving toward classifying 7-OH as a Schedule I substance, paving the way for a nationwide ban after a DEA review. The FDA cites safety concerns and industry reports as justification for tighter controls and stronger public education.
Kratom has grown in popularity worldwide, including in the United States, where it appears in energy drinks, gummies, and various supplements sold in stores and online. The concern centers on concentrated or synthetic products containing 7-OH, which researchers warn can be more potent than morphine. The FDA emphasizes the urgency of regulation to protect consumers and to raise awareness of associated risks.